A BluePrint HER2‑Type result means that the tumor’s gene expression profile shows HER2‑driven biology, indicating that HER2 signaling is a dominant pathway driving tumor growth, regardless of how the tumor appears by standard pathology alone. This result reflects functional HER2 activity, not just receptor presence on the cell surface.